![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00085891 |
The purpose of this study is to demonstrate superior efficacy of sustained release quetiapine compared to placebo in patients with schizophrenia after receiving treatment for up to 6 weeks.
Condition | Intervention | Phase |
Schizophrenia |
Drug: Quetiapine Fumarate |
Phase III |
MedlinePlus related topics: | Schizophrenia |
ChemIDplus related topics: | Quetiapine Quetiapine fumarate |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia |
Estimated Enrollment: | 535 |
Study Start Date: | June 2004 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
![]() |
Show 29 Study Locations |
AstraZeneca |
Study Director: | AstraZeneca Seroquel Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1444C00133 |
First Received: | June 16, 2004 |
Last Updated: | February 14, 2006 |
ClinicalTrials.gov Identifier: | NCT00085891 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |